Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)

Emma M Kileel; Carlos D Malvestutto; Janet Lo; Kathleen V Fitch; Carl J Fichtenbaum; Judith A Aberg; Markella V Zanni; Esteban Martinez; Nwora Lance Okeke; Princy Kumar; Esau Joao; Sara H Bares; Daniel Berrner; Marek Smieja; Jhoanna C Roa; Sara McCallum; Pamela S Douglas; Heather J Ribaudo; Steven K Grinspoon

doi:10.1093/cid/ciad107

Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)

Clin Infect Dis. 2023 Jun 8;76(11):2010-2013. doi: 10.1093/cid/ciad107.

Authors

Emma M Kileel¹, Carlos D Malvestutto², Janet Lo¹, Kathleen V Fitch¹, Carl J Fichtenbaum³, Judith A Aberg⁴, Markella V Zanni¹, Esteban Martinez⁵, Nwora Lance Okeke^{6

7}, Princy Kumar⁸, Esau Joao⁹, Sara H Bares¹⁰, Daniel Berrner¹¹, Marek Smieja¹², Jhoanna C Roa¹³, Sara McCallum¹, Pamela S Douglas¹⁴, Heather J Ribaudo¹⁵, Steven K Grinspoon¹

Affiliations

¹ Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
² Division of Infectious Diseases, Ohio State University Medical Center, Columbus, Ohio, USA.
³ Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
⁴ Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
⁵ Infectious Diseases Service, Hospital Clinic and University of Barcelona, Barcelona, Spain.
⁶ Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
⁷ Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
⁸ Division of Infectious Diseases and Travel Medicine, Georgetown University School of Medicine, Washington, DC, USA.
⁹ Infectious Diseases Department, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil.
¹⁰ Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.
¹¹ University of California-San Francisco at Zuckerberg San Francisco General Hospital, San Francisco, California, USA.
¹² Division of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
¹³ DLH Corporation, Silver Spring, Maryland, USA.
¹⁴ Duke University Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
¹⁵ Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

Abstract

Over 2-years of follow-up, integrase strand transfer inhibitor (INSTI)-use was associated with weight gain among those on an INSTI <2 years at entry (+0.27 kg/m2/year; 95% confidence interval [CI], .22 to .33 vs +0.17 kg/m2/year; 95% CI, .12 to .23; P = .01), but not those on an entry INSTI >2 years.

Keywords: HIV; body mass index (BMI); integrase strand transfer inhibitors (INSTIs); weight.

Publication types

Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Body Mass Index
Drug Resistance, Viral
HIV Infections* / drug therapy
HIV Infections* / prevention & control
HIV Integrase Inhibitors* / pharmacology
HIV Integrase Inhibitors* / therapeutic use
HIV Integrase*
HIV-1*
Humans

Substances

HIV Integrase Inhibitors
HIV Integrase

Abstract

Publication types

MeSH terms

Substances

Grants and funding